Category Archives: Neurology

Research Nester published a report titled In-Vitro Diagnostics for Cardiology and Neurology Market: Global Demand Analysis & Opportunity Outlook 2031 which delivers detailed overview of the global in-vitro diagnostics for cardiology and neurology market in terms of market segmentation by product type, technology, end user, and by region.

Further, for the in-depth analysis, the report encompasses the industry growth indicators, restraints, supply and demand risk, along with detailed discussion on current and future market trends that are associated with the growth of the market.

Theglobal in-vitro diagnostics for cardiology and neurology marketis estimated to occupy a sizeable revenue by growing at a CAGR of ~6% during the forecast period, i.e., 2022 2031, ascribing to the rising adoption of point-of-care testing devices to boost the demand for in-vitro diagnostics tests. Along with this, growing prevalence of chronic disorders across the globe, and escalating awareness levels associated with disease diagnosis, and rapidly increasing geriatric population are also expected to accelerate the growth of the market in the upcoming years.

The market is segmented by product type, technology and end user. Based on type, the reagents & consumables segment is anticipated to acquire the largest share during the forecast period on the back of the high precision and accurate diagnosis provided by recently developed reagents & consumables. Additionally, by end user, the hospitals segment is projected to grab the largest share over the forecast period attributing to the tremendous amount of diagnostic testing required to support a clinical decision for enhancing patient discovery, which is only possible in a hospital facility.

For More Information About This Report Visit:https://www.researchnester.com/sample-request-3849

Geographically, the global in-vitro diagnostics for cardiology and neurology market is segmented into five major regions, namely North America, Europe, Latin America, Asia Pacific, and the Middle East & Africa. Asia Pacific is evaluated to witness noteworthy growth in the market during the forecast period. This can be attributed to the rising investments by healthcare providers for improving the diagnostics infrastructure in the region. Moreover, the market in North America is assessed to acquire the largest share over the forecast period ascribing to the high healthcare spending, and strong presence of market players in the region.

The research is global in nature and covers detailed analysis on the market in North America (U.S., Canada), Europe (U.K., Germany, France, Italy, Spain, Hungary, Belgium, Netherlands & Luxembourg, NORDIC [Finland, Sweden, Norway, Denmark], Poland, Turkey, Russia, Rest of Europe), Latin America (Brazil, Mexico, Argentina, Rest of Latin America), Asia-Pacific (China, India, Japan, South Korea, Indonesia, Singapore, Malaysia, Australia, New Zealand, Rest of Asia-Pacific), Middle East and Africa (Israel, GCC [Saudi Arabia, UAE, Bahrain, Kuwait, Qatar, Oman], North Africa, South Africa, Rest of Middle East and Africa). In addition, analysis comprising market size, Y-O-Y growth & opportunity analysis, market players competitive study, investment opportunities, demand for future outlook etc. has also been covered and displayed in the research report.

Growing Occurrence of Chronic Disorders Around the World to Bolster Market Growth

Since the last few years, the prevalence of several cardiovascular and neurological diseases is increasing significantly. This is resulting in the rise in awareness regarding early diagnosis among the population and an increase in routine diagnosis, which in turn is anticipated to boost the demand for advanced in-vitro diagnostics products in the near future.

However, the expensiveness of in-vitro diagnostics instruments is expected to operate as key restraint to the growth of the global in-vitro diagnostics for cardiology and neurology market over the forecast period.

This report also provides the existing competitive scenario of some of the key players of the global in-vitro diagnostics for cardiology and neurology market which includes company profiling of Thermo Fisher Scientific Inc., F. Hoffman-La Roche Ltd, Sysmex Corporation, Siemens AG, Becton, Dickinson, and Company, DiaSorin S.p.A., Quest Diagnostics, Inc., Bio-Rad Laboratories, Inc., Abbott Laboratories, Danaher Corporation, and others. The profiling enfolds key information of the companies which encompasses business overview, products and services, key financials and recent news and developments. On the whole, the report depicts detailed overview of the global in-vitro diagnostics for cardiology and neurology market that will help industry consultants, equipment manufacturers, existing players searching for expansion opportunities, new players searching possibilities and other stakeholders to align their market centric strategies according to the ongoing and expected trends in the future.

Get a Sample Copy Of This Report With Graphs and Charts:https://www.researchnester.com/sample-request-3849

Research Nester is a one-stop service provider, leading in strategic market research and consulting with an unbiased and unparalleled approach towards helping global industrial players, conglomerates and executives to make wise decisions for their future investment and expansion by providing them qualitative market insights and strategies while avoiding future uncertainties. We believe in honesty and sheer hard work that we trust is reflected in our work ethics. Our vision is not just limited to gain the trust of our clients but also to be equally respected by our employees and being appreciated by the competitors.

For more information, please contact:

AJ Daniel

Research NesterEmail: [emailprotected]Tel: +1-6465869123

Related Links

Animal Healthcare MarketWriting Instruments MarketSupercapacitor MarketIndustrial Salt MarketAutomotive Lightweight Material MarketDrug (Medicine) Dispenser MarketOffice Furniture MarketPC Accessories MarketU.S. 3D Printing Market3D Printed Medical Device Market

Read the original:
Global In-Vitro Diagnostics For Cardiology And Neurology Market Driving Factors, Industry Growth, And Forecast To 2031 ChattTenn Sports - ChattTenn...

SAN DIEGO, CA, March 31, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- Sigyn Therapeutics, Inc. (OTC Markets:SIGY), a medical technology company focused on the treatment of pathogen-associated conditions that induce sepsis and other life-threatening disorders, today announced the appointment of Ajay Verma, M.D., Ph.D.to its Scientific Advisory Board.

Dr. Verma is a recognized thought leader in the field of neurology. His extensive clinical experience and resulting insights are anticipated to contribute to the continued advancement of Sigyn Therapy. Sigyn Therapy is an extracorporeal blood purification technology being advanced to treat life-threatening inflammatory disorders.

Dr. Verma is a neurologist, neuroscientist, drug developer, inventor, and biotech science advisor. Dr. Verma most recently headed R&D efforts at Yumanity Therapeutics, developing drugs against novel targets for treating neurodegenerative diseases. Prior to that he was the EVP of Research and Experimental Medicine at Codiak Biosciences. He has also served as CMO at United Neuroscience (now called Vaxxinity), VP of Neurology at Biogen and Novartis, and Director of Neuroscience Experimental Medicine at Merck. His drug development experience spans small molecule, peptide/protein, antibody, oligonucleotide, vaccine, and exosome drug platforms. He has largely focused on translational and early clinical development in neurology indications using precision drug development approaches that leverage biomarkers and experimental medicine paradigms. Prior to his Biopharma career, Dr. Verma was Professor of Neurology at the Uniformed Services University of the Health Sciences. He also worked as a staff neurologist at the Walter Reed Army Medical Center for 11 years after completing his neurology residency there. He received his M.D. and Ph.D. from Johns Hopkins University, where he trained in the laboratory of Dr. Solomon Snyder. He received his B.S. in Zoology from the University of Maryland.

About Sigyn Therapeutics

Sigyn Therapeutics is a medical technology company focused on the treatment of pathogen-associated conditions that precipitate sepsis, the leading cause of hospital deaths worldwide. Sigyn Therapy is a multi-function blood purification technology that extracts pathogen sources of life-threatening inflammation in concert with the broad-spectrum elimination of inflammatory mediators from the bloodstream.

Beyond establishing a novel strategy to combat sepsis, candidate treatment indications for Sigyn Therapy include, but are not limited to; emerging pandemic threats, hepatic encephalopathy, bridge to liver transplant, and community-acquired pneumonia (CAP), which is a leading cause of death among infectious diseases, the leading cause of death in children under five years of age, and a catalyst for approximately 50% of sepsis and septic shock cases.

To learn more, visit http://www.SigynTherapeutics.com

Cautionary Note Regarding Forward-Looking Statements

This information in this press release contains forward-looking statements of Sigyn Therapeutics, Inc. (Sigyn) that involve substantial risks and uncertainties. All statements contained in this summary are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 that involve risks and uncertainties. Statements containing words such as "may," "believe," "anticipate," "expect," "intend," "plan," "project," "will," "projections," "estimate," "potentially" or similar expressions constitute forward-looking statements. Such forward-looking statements are subject to significant risks and uncertainties and actual results may differ materially from the results anticipated in the forward-looking statements. These forward-looking statements are based upon Sigyn's current expectations and involve assumptions that may never materialize or may prove to be incorrect. Factors that may contribute to such differences may include, without limitation, the Company's ability to clinically advance Sigyn Therapy in human studies required for market clearance, the Company's ability to manufacture Sigyn Therapy, the Company's ability to raise capital resources, and other potential risks. The foregoing list of risks and uncertainties is illustrative but is not exhaustive. Additional factors that could cause results to differ materially from those anticipated in forward-looking statements can be found under the caption "Risk Factors" in the Company's Annual Report on Form 10-K for the year ended December 31, 2020, and in the Company's other filings with the Securities and Exchange Commission, including its quarterly Reports on Form 10-Q. All forward-looking statements contained in this report speak only as of the date on which they were made. Except as may be required by law, the Company does not intend, nor does it undertake any duty, to update this information to reflect future events or circumstances.

Contacts:

Stephen Kilmer

Sigyn Therapeutics, Inc.

Investor Relations

(646) 274-3580

stephen@sigyntherapeutics.com

Media Contacts:

Russo Partners, LLC

David Schull

(212) 845-4271

David.Schull@russopartnersllc.com

Nic Johnson

(212) 845-4242

Nic.Johnson@russopartnersllc.com

Go here to read the rest:
Sigyn Therapeutics Appoints Ajay Verma, MD, Ph.D. to its Scientific Advisory Board - GlobeNewswire

Whether stress-induced or genetic, headaches are a common condition that can affect anyone. This includes neurologists AKA the specialists who treat headache disorders.

Headache is any pain affecting the head, upper face or upper neck. Headaches are called primary when they arise from biological changes within the brain itself, Robert Kaniecki, the director of the UPMC Headache Center in Pittsburgh, told HuffPost. These include migraine headaches, tension-type headaches, and cluster headaches.

Migraine-induced headaches cause additional symptoms such as nausea, sensitivity to light and noise, fatigue, visual disturbances and more. People may also experience secondary headaches if there is another underlying illness or cause for the headache, Kaniecki said.

Worldwide, headache disorders are considered one of the most common yet under-treated disorders of the nervous system. Additionally, a 2018 study found that one in six people in the U.S. reported having a migraine or severe headache over a three-month period.

HuffPost spoke to neurologists about the things they personally do when experiencing a headache, and why these go-to strategies work.

Find a calming space.

Creating a quiet and relaxing environment is often the first step some neurologists take to alleviate headache pain.

If I have a headache, I rest or lie down for as long as I can, and it doesnt depend on the time of day, said Faye Begeti, a neurology doctor and neuroscientist in the U.K. With migraines in particular, people usually find that they have to lie down in a quiet, dark room.

Distract your mind.

With busy schedules and responsibilities, taking a quick siesta isnt always feasible. Rami Burstein, a professor of anesthesia and neuroscience at Harvard Medical School, explained that he tends to utilize relaxing distractions when he cant power nap in the workplace.

As contrary as it may sound, walking can be helpful and reading, Burstein said.

Figure out your triggers.

Understanding your headache triggers can serve as both a preventative and in-the-moment approach to address pain.

Most of my migraine attacks are visually triggered or are triggered when I am ambivalent or worried about a decision or situation. The latter is a bit harder to control, but its fascinating to recognize, said Jan Lewis Brandes, the director and founder of the Nashville Neuroscience Group. Red wine can be a trigger for me, so I am careful about not having more than a few ounces.

Additionally, a common headache trigger is sleep disturbances. Theres a misconception that headaches are primarily caused by sleep deprivation, but Begeti explained that sticking to a consistent sleep schedule may be more important than the amount of sleep you get every night.

This is something that I didnt know when I was at university, so I would reliably have a headache every single Saturday after staying up late the day before, and sleeping in on the weekend, Begeti said.

Westend61 via Getty Images

Get hydrated ASAP.

Many neurologists pay closer attention to what they drink when experiencing headache pain. As simple as it sounds, water is your best friend when you have a headache or migraine.

Kristina Lopez, an assistant professor at the West Virginia University Rockefeller Neuroscience Institute and headache specialist, said that her headaches are typically a signifier that she needs to up her hydration. While Lopez explained that researchers arent quite sure why drinking water eases headache pain (there are a number of theories), its a cheap and safe preventative and as-needed treatment strategy.

I finally took my own advice and started getting a consistent eight hours of sleep and drinking more water, Lopez said. Its wild how much better I feel.

Try drinking a little coffee, too.

Though it may seem counterintuitive, caffeine can actually be a remedy for headaches. Brandes said that drinking a cup of coffee is the first step she takes when combatting a migraine attack, followed by drinking a glass of water and taking medication.

Caffeine causes blood vessels to narrow and restricts blood flow around the brain, which can relieve pain. However, moderation is key: Consuming caffeine on the regular may have the opposite effect, leading to withdrawal headaches if you suddenly stop drinking your morning espresso or green tea.

Eat smaller meals throughout the day.

Interestingly, another personal tip from Kanieki is to break snacks and meals into five to six portions throughout the day.

This is because low blood sugar may exacerbate headache pain, along with migraine symptoms. Try swapping up your meal times or breaking down bigger meals into smaller parts that you eat intermittently and see if it helps.

Take pain relievers when necessary.

Depending on the severity of her headache, Begeti will take over-the-counter pain medication such as non-steroidal anti-inflammatory drugs (aka NSAIDs) or acetaminophen. However, be sure to keep track of the amount of pain relievers you take: Begeti noted that she limits her monthly intake of over-the-counter pain medication to under 10 days a month to avoid medication-overuse headaches.

If you are experiencing more severe pain or symptoms, it may be worth a trip to the neurologist to see if you could benefit from prescription medication.

I get migraine attacks and will take a triptan an as-needed migraine pain medication and a nausea medication when I feel an episode coming on, Lopez said.

Remember that some factors are outside of your control.

While some things can help you prevent headache pain, its important to note that not every headache can be linked to lifestyle or environmental factors.

Sometimes there are no notable triggers to headaches, Begeti said. A big part of why people get headaches is due to genetics, and I see headaches that run in families.

Headache pain can range from mild to debilitating. Trying neurologist-approved strategies until you find what specifically works for you may help to alleviate your pain in the long run. Establishing a unique, at-home routine is vital to treating these conditions effectively.

Its important to listen to your body. I find that a headache may resolve if I do that and it certainly prevents it from getting worse, Begeti said.

Read this article:
8 Things Neurologists Do When They Have A Headache - HuffPost

SYRACUSE, N.Y. (WSYR-TV) Central New York has the highest population of patients with Multiple Sclerosis (MS) in the nation. Doctors have been speculating why for years, and it may be getting worse.

A neurologist at St. Josephs Health is concerned about the trend hes seen throughout the pandemic.

Dr. Fahed Saada recently treated a 24-year-old man. His brain and spine were riddled with lesions. Hes in the early stages of MS and joins a growing list of Saadas patients, adding to a trend no neurologist wants to see.

Ive never seen so many acute Multiple Sclerosis cases over the years compared to this past year and I dont know why.

Saada says other viruses can increase our risk, but it will be years before we learn COVID-19s contributions, if any. In the meantime, more people are getting sick.

Early treatment can give patients some improvement, but over time, MS progresses.

The disease disrupts the brains ability to send messages to the rest of the body. Theres no cure, and eventually, it causes permanent damage to the nerves.

These lesions, if theyre not treated appropriately and quickly, they become what we call black holes in the brain.

Its hard to stop an uptick in cases when doctors dont know whats causing it.

However, neurologists do know that places north of the equator are at a higher risk because patients with MS have low vitamin D levels.

Doctors also know we here in Central New York dont get a lot of sunlight in the winter.

For now, though, Saada says its a medical mystery doctors desperately want to solve.

Saada says a vitamin D supplement may help boost your prevention, but you should always talk to your doctor before making any changes to your medication and supplements.

See the original post:
Wellness Wednesday: neurologist concerned about Multiple Sclerosis trend hes seen throughout the pandemic - WSYR

Our search found 37 bedside clinical tests or groups of tests for motor FND (functional weakness and functional movement disorder) that had some formal validation (table 2). Sample size varied between 8 and 107 patients with FND. Most investigations of positive signs were conducted in a single study or a small number of studies (maximum five for the Hoover sign), allowing for the calculation of pooled specificity and sensitivity by merging data from different studies. Five studies reported on the inter-rater reliability of positive signs.

Overall, the specificities of validated signs are high, ranging from 64% to 100%; however, the sensitivities are lower, ranging from 9% to 100%. Inter-rater reliability of these signs is overall good to excellent (defined as values: <0.2 poor/0.21-0.4 fair/0.41-0.6 moderate/0.61-0.8 good/>0.8 excellent).

General signs common to all FND presentations are: variability of the symptom, which can be observed during history taking and examination, and effortful or grimacing expression while following the examiners instructions during examination. If suspecting a functional movement disorder, test oculomotor function to show abnormal eye movements and in particular convergence spasm,100 even if the patient did not endorse this as a concern during history taking.

When assessing gait, look for typical positive signs such as monoplegic leg dragging, excessive visible effort (huffing and puffing sign),50 falling toward support (chair nearby, table, wall), excessive slowness, hesitation or caution, non-economic posture (for example knee flexed), and knee buckling (sudden loss of tone at each step).101 Asking a patient with severe gait disorder to propel a chair while sitting on it will show improvement in FND.51

When assessing hemifacial spasm, look for typical signs such as long contraction of more than three seconds, lip pulling (tonic deviation of the lip, often the lower one) sometimes with platysma contraction, and lack of other Babinski sign for hemifacial spasm (other Babinski sign=eyebrow elevation on the side of the spasm).102 Positive signs for functional orofacial movements in comparison with tardive dyskinesia are: lack of chewing movements, lack of self-biting, lingual movements without mouth movements, and abnormal speech.45 A large case series (61 patients) that focused on facial functional movement103 reported involvement of the lip as the most frequent (60.7%, with the lip pulling feature).

When assessing movements of the trunk, look for the typical positive sign of asymmetry in strength of the sterno-cleido-mastoid muscle.53 A functional Romberg sign is described as large movements of imbalance with sudden steps and no falls and improvement with cognitive distraction or numbers drawn on the back.48

When assessing episodes of cataplexy (brief, symmetrical loss of muscle tone with retained consciousness precipitated by strong emotions) look for positive signs54 such as lack of sudden facial expression change, facial jerks or grimaces, postural dyscontrol (head drop, trunk fall), in addition to preserved tendon reflexes (which typically disappear during cataplexy associated with narcolepsy).

When assessing upper arm weakness, look for discordance or inconsistency in strength (at different instances during the examination), as well as a give-way/collapsing pattern, drift without pronation, and/or co-contractions of agonist and antagonist muscles preventing movement of the tested joint. As a cautionary note, give-way/collapsing pattern of weakness is common in patients with pain limited weakness (and pain limited weakness should not be mistaken for functional limb weakness).104 In cases of complete hand plegia, involuntary abduction of the fifth finger can be seen when the patient is asked to do a forced abduction against the examiners resistance on the healthy hand.58 The flex-ext sign, which is the equivalent of the Hoover sign,105 can be elicited as follows: the involuntary flexion of the arm at the elbow that occurs when the patient focuses on extending the healthy elbow against the examiners resistance is better than the voluntary flexion.59

When assessing lower limb weakness, also look for discordance/inconsistence, give-way/collapsing weakness, co-contractions, and the Hoover sign.61 The classical way to describe a positive Hoover sign is when the involuntary hip extension (when the patient focuses on flexing the healthy leg against the examiners resistance) is stronger than the voluntary hip extension. A similar pattern can be found during leg abduction60: when the patient is asked to do a forced abduction with both legs against the examiners resistance, the weak leg will have a stronger involuntary abduction than when the voluntary abduction is tested. In patients with severe unilateral leg weakness, positioning passively the leg in flexion with the soles on the bed (spinal injury test)62 shows a discordance in strength as the weak leg will not fall on the side, as expected in complete weakness.

When assessing tremor, typical signs are distractibility, entrainment, and increase in amplitude with weight load on the wrists. In addition, look for variability in amplitude, frequency, and direction of tremor.63 A whack a mole sign can be seen106: when the limb affected by tremor is immobilized by the examiner, the tremor appears in another body segment (head, trunk, other arm, or legs).

No validated clinical signs are available for assessing dystonia, but a pattern of adult sudden onset fixed dystonia (typically clenched fist sparing thumb and index finger107) or equinovarus foot is suggestive of functional dystonia.108 Associated prominent pain and other FND signs can help support the diagnosis.109

When assessing tics, no validated signs are available but clinical clues can help identify functional tics110111: lack of premonitory urge and inability to suppress the movement, female preponderance, additional FND symptoms, lack of response to anti-tic medication, and absence of family history. In functional tics, the cranial region is less affected, the type of tic is often blocking (ie, interferes with voluntary action) and pali, echo, and copro phenomenon are less common.

Overall, the evidence for rule-in motor signs shows very high specificity, which advocates for their routine use in clinical practice. A range of educational pictorial and video libraries illustrate many of these signs.2101102112113 Too much emphasis on a single sign, however, can lead to false positives. In a cohort of 190 patients diagnosed with a neurological disorder, 37 (20%) had at least one positive functional neurological sign.91 Interestingly, regression analysis showed that this 20% of the cohort had typical risk factors known in patients with FND, suggesting that the presence of positive signs in this subgroup could either be false positives or indicate the presence of an FND comorbidity. Keep in mind the possibility that the patient has both FND and another neurological disorder: recent reports describe functional neurological signs in a subset of patients with Parkinsons disease114115 or multiple sclerosis.116 Overall, data from a systematic review and a prospective study underscore that rates of misdiagnosis in FND since 1970 (once confirmed) are low, and between 1% and 4%.117118

Recently, efforts have been made to integrate additional clinical features in the process of diagnosis, such as, for example, abrupt onset, fluctuations of the motor symptom, comorbid pain, and fatigue.119 The presence of these features should raise the index of suspicion and prompt a more systematic search of signs positive for FND.

View post:
Diagnosis and management of functional neurological disorder - The BMJ

This article was originally published here

Disabil Rehabil. 2022 Jan 27:1-32. doi: 10.1080/09638288.2022.2028911. Online ahead of print.

ABSTRACT

PURPOSE: Peer-based interventions are increasingly popular and cost-effective therapeutic opportunities to support others experiencing similar life circumstances. However, little is known about the similarities and differences among peer-based interventions and their outcomes for people with neurological conditions. This scoping review aims to describe and compare the characteristics of existing peer-based interventions for adults with common neurological conditions.

MATERIALS AND METHODS: We searched MEDLINE, CINAHL, PsychInfo, and Embase for research on peer-based interventions for individuals with brain injury, Parkinsons, multiple sclerosis, spinal cord injury, and stroke up to June 2019. The search was updated in March 2021. Fifty-three of 2472 articles found were included.

RESULTS: Characteristics of peer-based intervention for this population vary significantly. They include individual and group-based formats delivered in-person, by telephone, or online. Content varied from structured education to tailored approaches. Participant outcomes included improved health, confidence, and self-management skills; however, these varied based on the intervention model.

CONCLUSION: Various peer-based interventions exist, each with its own definition of what it means to be a peer. Research using rigorous methodology is needed to determine the most effective interventions. Clear definitions of each program component are needed to better understand the outcomes and mechanism of action within each intervention.IMPLICATIONS FOR REHABILITATIONRehabilitation services can draw on various peer support interventions to add experiential knowledge and support based on shared experience to enhance outcomes.Fulfilling the role of peer mentor may be beneficial and could be encouraged as part of the rehabilitation process for people with SCI, TBI, Stroke, PD, or MS.In planning peer-based interventions for TBI, Stroke, SCI, PD, and MS populations, it is important to clearly define intervention components and evaluate outcomes to measure the impact of the intervention.

PMID:35085058 | DOI:10.1080/09638288.2022.2028911

See the original post here:
Characteristics of peer-based interventions for individuals with neurological conditions: a scoping review - DocWire News